EIM
Essex Investment Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-266
| Closed | -$12.1K | – | 339 |
|
|
2023
Q3 | $12.1K | Hold |
266
| – | – | ﹤0.01% | 342 |
|
|
2023
Q2 | $14.9K | Sell |
266
-215
| -45% | -$12.1K | ﹤0.01% | 349 |
|
|
2023
Q1 | $21.8K | Hold |
481
| – | – | ﹤0.01% | 343 |
|
|
2022
Q4 | $20K | Sell |
481
-17,701
| -97% | -$736K | ﹤0.01% | 347 |
|
|
2022
Q3 | $1.19M | Buy |
18,182
+5,668
| +45% | +$370K | 0.19% | 159 |
|
|
2022
Q2 | $760K | Sell |
12,514
-18,297
| -59% | -$1.11M | 0.12% | 219 |
|
|
2022
Q1 | $1.93M | Sell |
30,811
-2,017
| -6% | -$127K | 0.24% | 128 |
|
|
2021
Q4 | $2.49M | Sell |
32,828
-1,146
| -3% | -$86.9K | 0.28% | 107 |
|
|
2021
Q3 | $3.8M | Buy |
33,974
+138
| +0.4% | +$15.4K | 0.47% | 58 |
|
|
2021
Q2 | $5.48M | Sell |
33,836
-1,704
| -5% | -$276K | 0.64% | 42 |
|
|
2021
Q1 | $4.33M | Buy |
+35,540
| New | +$4.33M | 0.53% | 45 |
|
|
2020
Q4 | – | Sell |
-41,966
| Closed | -$3.51M | – | 484 |
|
|
2020
Q3 | $3.51M | Sell |
41,966
-60
| -0.1% | -$5.02K | 0.5% | 47 |
|
|
2020
Q2 | $3.09M | Sell |
42,026
-9,345
| -18% | -$687K | 0.51% | 53 |
|
|
2020
Q1 | $2.18M | Sell |
51,371
-32,077
| -38% | -$1.36M | 0.44% | 60 |
|
|
2019
Q4 | $5.08M | Buy |
83,448
+4,629
| +6% | +$282K | 0.62% | 30 |
|
|
2019
Q3 | $3.23M | Sell |
78,819
-6,780
| -8% | -$278K | 0.47% | 52 |
|
|
2019
Q2 | $4.03M | Buy |
+85,599
| New | +$4.03M | 0.55% | 36 |
|
|
2018
Q3 | – | Sell |
-40,939
| Closed | -$2.41M | – | 411 |
|
|
2018
Q2 | $2.41M | Buy |
40,939
+19,149
| +88% | +$1.13M | 0.3% | 101 |
|
|
2018
Q1 | $996K | Sell |
21,790
-29,290
| -57% | -$1.34M | 0.13% | 208 |
|
|
2017
Q4 | $1.2M | Buy |
+51,080
| New | +$1.2M | 0.16% | 198 |
|